Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Four-Part, Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Adults With Moderate to Severe Pachyonychia Congenita

Next Previous
Trial Profile

A Multicenter, Four-Part, Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Adults With Moderate to Severe Pachyonychia Congenita

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Pachyonychia congenita
  • Focus Registrational; Therapeutic Use
  • Acronyms VALO
  • Sponsors Palvella Therapeutics

Most Recent Events

  • 29 Aug 2024 Status changed from active, no longer recruiting to completed.
  • 23 Dec 2020 Primary endpoint of Patient Global Assessment of Activities difficulties (PGA-AD), which compared the last two weeks of the Phase 2 open-label treatment period to the last two weeks of the RI period (phase II portion) has been met, according to results presented in the Palvella Therapeutics media release.
  • 23 Dec 2020 Primary endpoint of Patient Global Assessment of Activities Scale (phase III portion) has not been met, according to results presented in the Palvella Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top